25710-26-3

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-5-NITRO-6-(1-PYRROLIDINYL)PYRIMIDINE is used as an active pharmaceutical ingredient for its antibacterial and antifungal properties, making it a valuable compound in the development of new drugs to combat resistant infections.
Used in Medicinal Chemistry:
4-CHLORO-5-NITRO-6-(1-PYRROLIDINYL)PYRIMIDINE is used as a building block in organic synthesis, allowing researchers to create novel drug candidates with improved efficacy and reduced side effects.
Used in Drug Discovery:
4-CHLORO-5-NITRO-6-(1-PYRROLIDINYL)PYRIMIDINE is utilized in the identification and development of new drug targets, contributing to the advancement of innovative therapeutic agents for various diseases and conditions.

Upstream product

• 123-75-1 pyrrolidine 
• 4316-93-2 4,6-dichloro-5-nitropyrimidine 

Downstream Products

• 90958-70-6 2,3-Dihydro-5-phenyl-7-N-pyrrolidino-1H-pyrimido<2,1-h>pteridine 6-oxide 
• 906648-23-5 [benzyl-(5-nitro-6-pyrrolidin-1-yl-pyrimidin-4-yl)-amino]-acetic acid methyl ester 
• 90958-71-7 2,3-Dihydro-5-phenyl-7-N-morpholino-1H-pyrimido<2,1-h>pteridine 6-oxide 

Relevant academic research and scientific papers

Thiazolopyrimidine compound and preparation method thereof Use and pharmaceutical compositions

The invention belongs to the technical field of medicines, and particularly relates to a thiazolopyrimidine compound as well as a preparation method, application and a pharmaceutical composition thereof. The thiazolopyrimidine compound is I inhibitor as shown in formula (PI3K), and can be used for preparing medicaments for preventing and/or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammations, metabolic dysfunction, endocrine dysfunction or nerve diseases.

Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors

As abnormal PI3K signaling is a feature of many types of cancer, the development of orally active PI3K inhibitors is of great significance for targeted cancer therapy. Through integrating strategies of reducing aromatic character/increasing the fraction of sp3 carbons together with scaffold hopping, we designed and synthesized two new series of thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives for use as PI3K inhibitors. Our structure–activity relationship studies led to the identification of thieno[2,3-d]pyrimidine 6a and thiazolo[5,4-d]pyrimidine 7a, which exhibited remarkable nanomolar PI3K potency, good antiproliferative activity, favorable pharmacokinetic properties and significant in vivo anti-cancer efficacy. Notably, thiazolo[5,4-d]pyrimidine 7a had better anti-cancer activity than thieno[2,3-d]pyrimidine 6a and is worthy of further pre-clinical evaluation for its use in cancer treatment.

Palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines with amines

A concise and efficient approach was developed for the synthesis of mono-substituted and di-substituted pyrimidines products via palladium-catalyzed amination of chloro-substituted 5-nitropyrimidines and amines. This synthetic methodology can produce vari